A clinical effectiveness study of Sodium phenylbutyrate in the treatment of polycystic ovary syndrome

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400086139

Enrollment

Unknown

Registered

2024-06-25

Start date

2024-07-01

Completion date

Unknown

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome

Interventions

PCOS:sodium phenylbutyrate treatment

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18-40 years old 2. Women 3.18.51.67mmol/L) or clinical hyperandrogenicity (modified Ferriman Galwey (mF-G)>4)

Exclusion criteria

Exclusion criteria: 1.Other endocrine diseases that can cause polycystic ovaries, such as 21 hydroxylase deficiency, prolactinoma, hypothyroidism, Cushing's syndrome, etc 2. Pregnancy or lactation status 3. Allergies to active ingredients and excipients of drugs 4. Suffering from other serious diseases or tumors of important organs such as heart, liver, and kidney 5. The researcher believes that the subjects have any other factors that may affect the efficacy or safety evaluation of this study and are not suitable for participation in this study

Design outcomes

Primary

Measure	Time frame
Total testosterone;HOMA-IR;	—

Secondary

Measure	Time frame
bilateral ovarian antral follicle count;menstrual cycle;bilateral ovarian volume;AMH;Sex hormone profile;Body weight;Waist circumference;Hip circumference;BMI;body fat ratio;Glycated hemoglobin;Blood lipids;	—

Countries

China

Contacts

Public ContactLiangshan Mu

Zhongshan Hospital, Fudan University

mu.liangshan@zs-hospital.sh.cn+86 188 1782 1283

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026